Unknown

Dataset Information

0

Model evaluation of target product profiles of an infant vaccine against respiratory syncytial virus (RSV) in a developed country setting.


ABSTRACT: Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract disease in children worldwide and is a significant cause of hospital admissions in young children in England. No RSV vaccine has been licensed but a number are under development. In this work, we present two structurally distinct mathematical models, parameterized using RSV data from the UK, which have been used to explore the effect of introducing an RSV paediatric vaccine to the National programme. We have explored different vaccine properties, and dosing regimens combined with a range of implementation strategies for RSV control. The results suggest that vaccine properties that confer indirect protection have the greatest effect in reducing the burden of disease in children under 5 years. The findings are reinforced by the concurrence of predictions from the two models with very different epidemiological structure. The approach described has general application in evaluating vaccine target product profiles.

SUBMITTER: Kinyanjui T 

PROVIDER: S-EPMC7037978 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Model evaluation of target product profiles of an infant vaccine against respiratory syncytial virus (RSV) in a developed country setting.

Kinyanjui Timothy T   Pan-Ngum Wirichada W   Saralamba Sompob S   Taylor Sylvia S   White Lisa L   Nokes D James DJ  

Vaccine: X 20200131


Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract disease in children worldwide and is a significant cause of hospital admissions in young children in England. No RSV vaccine has been licensed but a number are under development. In this work, we present two structurally distinct mathematical models, parameterized using RSV data from the UK, which have been used to explore the effect of introducing an RSV paediatric vaccine to the National programme. We have explored d  ...[more]

Similar Datasets

| S-EPMC5221409 | biostudies-literature
2024-05-29 | GSE232687 | GEO
| PRJNA973580 | ENA
2022-04-24 | GSE197868 | GEO
| S-EPMC9147281 | biostudies-literature
| S-EPMC6615606 | biostudies-literature
| S-EPMC7556875 | biostudies-literature
| S-EPMC9888399 | biostudies-literature
| S-EPMC10960893 | biostudies-literature
| S-EPMC7661211 | biostudies-literature